ABCC10: A promising drug target and biomarker for the treatment of various diseases

Target Name: ABCC10

NCBI ID: G89845

ABCC10

ABCC10: A promising drug target and biomarker for the treatment of various diseases

Abstract:

ABCC10 (Endoplasmic Reticulum Chaperone 10) is a protein that plays a crucial role in the regulation of endoplasmic reticulum (ER) traffic, which is a critical process for the transport of proteins from the cell surface to the ER. The abnormal function of ABCC10 has has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we discuss the current understanding of ABCC10 as a drug target and biomarker, and the potential therapeutic applications of targeting this protein in disease treatment.

Introduction:

The endoplasmic reticulum (ER) is a specialized organ that plays a vital role in the regulation of protein function and quality control. It is the final destination for the majority of newly synthesized proteins, and it is responsible for sorting and transporting them to their final destinations for protein folding and degradation. The ER is also responsible for removing damaged or unnecessary proteins, which is crucial for maintaining the protein homeostasis and preventing the buildup of harmful substances in the cell.

ABCC10 is a protein that is expressed in most tissues and is involved in the regulation of ER traffic. It is a member of the transmembrane protein (TMP) family and is characterized by its unique structure, which consists of a long cytoplasmic tail and a transmembrane domain. The cytoplasmic tail of ABCC10 is rich in various domains, including a hydrophobic region, a hydrophilic region, and a variable region.

In recent years, the study of ABCC10 has revealed its involvement in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. One of the most significant findings is the involvement of ABCC10 in cancer progression. Several studies have shown that ABCC10 is overexpressed in Various types of cancer, including breast, lung, and colorectal cancer. Overexpression of ABCC10 has been associated with the development of cancer-related traits, such as increased cell motility, enhanced invasion and metastasis, and poor prognosis.

Another promising application of ABCC10 is its potential as a biomarker for various diseases. The overexpression of ABCC10 has been shown to be associated with the development of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, the analysis of ABCC10 levels in brain tissue has shown that overexpression is associated with increased neurofibrillary tangles and reduced neurotrophic factor (NTF) levels, which are markers of neurodegeneration. Therefore, targeting ABCC10 with drugs or other therapeutic approaches may be a promising strategy for the treatment of these disorders.

Targeting ABCC10:

Several studies have shown that targeting ABCC10 with small molecules or antibodies can significantly improve the efficacy of cancer treatments. One of the most promising strategies is the use of small molecules that can inhibit the activity of ABCC10. Several studies have shown that inhibitors of ABCC10, such as 1-fluorooctan-1-amine (FFA) and 2-fluorooctan-1-amine (FoO), can significantly reduce the overexpression of ABCC10 in cancer cells. Additionally, antibodies that specifically target ABCC10 have been shown to be effective in preclinical studies for the treatment of various diseases, including cancer.

Another approach to targeting ABCC10 is the use of cross-talk inhibitors, which are drugs or compounds that can inhibit the activity of other proteins that are involved in the same signaling pathway as ABCC10. Cross

Protein Name: ATP Binding Cassette Subfamily C Member 10

Functions: ATP-dependent transporter of the ATP-binding cassette (ABC) family that actively extrudes physiological compounds, and xenobiotics from cells. Lipophilic anion transporter that mediates ATP-dependent transport of glucuronide conjugates such as estradiol-17-beta-o-glucuronide and GSH conjugates such as leukotriene C4 (LTC4) (PubMed:12527806, PubMed:15256465). May contribute to regulate the transport of organic compounds in testes across the blood-testis-barrier (Probable). Mediates multidrug resistance (MDR) in cancer cells by preventing the intracellular accumulation of certain antitumor drugs, such as, docetaxel and paclitaxel (PubMed:15256465, PubMed:23087055). Does not transport glycocholic acid, taurocholic acid, MTX, folic acid, cAMP, or cGMP (PubMed:12527806)

The "ABCC10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ABCC10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets